JAK inhibitor
- Blocks cytokine signaling — immunosuppression
- Infection risk, including herpes zoster
- Boxed warnings for thrombosis and malignancy
Drugs with this mechanism (10)
- Abrocitinib — Oral JAK1 inhibitor for refractory atopic dermatitis; carries the JAK class boxed warning.
- Baricitinib — Oral JAK1/JAK2 inhibitor for rheumatoid arthritis, alopecia areata, and severe COVID-19.
- Fedratinib — JAK2/FLT3 inhibitor for myelofibrosis.
- Momelotinib — JAK/ACVR1 inhibitor for myelofibrosis with anemia; improves spleen, symptoms, and transfusion burden.
- Pacritinib — JAK2 inhibitor that spares JAK1; designed for myelofibrosis with severe thrombocytopenia.
- Peficitinib — Oral JAK inhibitor used for rheumatoid arthritis in some countries; serious infection and herpes-zoster risks.
- Ritlecitinib — Oral JAK3/TEC-family inhibitor for severe alopecia areata; immunosuppression drives the risk.
- Ruxolitinib — JAK1/2 inhibitor for myelofibrosis and polycythemia vera; abrupt stop causes a cytokine flare.
- Tofacitinib — First oral JAK inhibitor; boxed warnings for thrombosis, malignancy and MACE.
- Upadacitinib — JAK1-selective inhibitor across rheumatology, dermatology and IBD.
All mechanisms · Open the interactive console ↗